Adrian Mercer
Metabolic Pharmacology Editor
Metabolic Science & Peptide Pharmacology
NovaEvum Research Editorial
Education
- Biochemistry, University of Toronto
- Pharmacology, Harvard University
Adrian Mercer covers metabolic pharmacology, peptide receptor signalling and emerging developments in multi-receptor agonist research for NovaEvum Research Editorial.
This specialization examines GLP-1, GIP, glucagon and related metabolic pathways, with particular attention to the molecular mechanisms underlying investigational compounds.
These articles evaluate peer-reviewed findings, experimental methods and emerging developments in metabolic science. The coverage evaluates relevant peer-reviewed literature from academic research communities, including Harvard University, the University of Toronto, Yale University and other international centres of metabolic research.
Topics covered
- Retatrutide
- Tirzepatide
- Semaglutide
- GLP-1
- GIP
- Glucagon
- Metabolic receptors
- Triple-receptor agonists
Research categories
University references in NovaEvum Research Editorial describe institutions whose published scientific literature may be examined in our editorial coverage. These references do not imply that NovaEvum or its authors are affiliated with, endorsed by, or collaborating with those institutions.
33 articles under this name
IllustrationGeneral6 min readPeptides in 2027: The Biggest Breakthroughs and Compounds to WatchThe peptide research to watch in 2027: retatrutide, cagrilintide and zenagamtide, MOTS-c, SS-31 after its Barth syndrome approval, and…Read article
IllustrationGLP-1 and metabolic7 min readRetatrutide in 2026: The Evolution of Triple-Receptor Metabolic ResearchRetatrutide research in 2026: how GLP-1, GIP and glucagon receptor agonism fit together, the October review on metabolic liver disease, and…Read article
IllustrationGLP-1 and metabolic7 min readRetatrutide and Sleep Apnea: What the TRIUMPH-OSA Trials FoundTwo phase 3 trials, published in NEJM in October 2026, tested retatrutide in moderate-to-severe obstructive sleep apnea.Read article
IllustrationL-Carnitine6 min readWhat Is L-Carnitine? The Carnitine Shuttle, the Evidence and Its StatusL-Carnitine carries fatty acids into mitochondria. How the carnitine shuttle works, where the clinical record sits, and what supplement…Read article
IllustrationGLP-1 and metabolic8 min readAmycretin: What the Trials of Novo Nordisk's GLP-1 and Amylin Agonist ShowAmycretin, now named zenagamtide, is one molecule acting at GLP-1 and amylin receptors. Its phase 1 and 2 results, AMAZE phase 3 trials and…Read article
IllustrationGLP-1 and metabolic9 min readAmylin receptors explained: the calcitonin receptor, RAMPs and AMY1 to AMY3There is no single amylin receptor gene. How the calcitonin receptor and three RAMPs form AMY1–AMY3, and what selectivity means for amylin…Read article
IllustrationGLP-1 and metabolic9 min readCagriSema Results: What the REDEFINE and REIMAGINE Trials ShowedCagriSema results from REDEFINE 1 and 2 and the REIMAGINE diabetes trials: endpoints, weight and HbA1c, tolerability, and what is still…Read article
IllustrationGLP-1 and metabolic9 min readEloralintide Phase 2: What the Amylin Agonist Trial ReportedEloralintide's 48-week phase 2 trial: design, weight results, nausea and fatigue rates, how amylin differs from GLP-1, and what phase 3…Read article
IllustrationGLP-1 and metabolic10 min readNew GLP-1 Drugs 2026: Approved and Late-Stage Incretin CompoundsA sourced October 2026 snapshot of new GLP-1 drugs: which incretin-class compounds are approved, where, and which are in phase 3.Read article
IllustrationGLP-1 and metabolic9 min readGLP-1 Hair Loss: What Tirzepatide and Semaglutide Trials ReportHair loss rates in tirzepatide and semaglutide trials versus placebo, why women report more, the weight-loss link, and what the data cannot…Read article
IllustrationGLP-1 and metabolic11 min readGLP-1 Muscle Loss: What Body-Composition Studies Actually MeasuredGLP-1 muscle loss: what DXA and MRI substudies of tirzepatide, semaglutide and retatrutide found, lean mass vs muscle, and add-on drug…Read article
IllustrationGLP-1 and metabolic10 min readGlucagon Receptor Agonists Explained: Why Glucagon Is Added to GLP-1 DrugsWhy survodutide, mazdutide, pemvidutide and retatrutide add glucagon receptor agonism: the energy and liver-fat hypotheses, and the…Read article
IllustrationGLP-1 and metabolic9 min readGray Market Retatrutide: What the Trial Evidence Can and Cannot TransferRetatrutide is investigational and approved nowhere. What its trials showed, why that evidence stays with the trial drug, and what case…Read article
IllustrationGLP-1 and metabolic9 min readMariTide (Maridebart Cafraglutide): Phase 2 Results and the GIPR Antagonist IdeaMariTide is Amgen's antibody-peptide conjugate: GLP-1 agonist and GIP receptor antagonist. Phase 2 results, MARITIME trials, and the GIPR…Read article
IllustrationGLP-1 and metabolic9 min readMazdutide: GLORY and DREAMS Trial Results and Approval StatusMazdutide is a GLP-1/glucagon dual agonist approved in China in 2025. What the GLORY obesity and DREAMS diabetes trials measured and found.Read article
IllustrationGLP-1 and metabolic9 min readRetatrutide Phase 3: The TRIUMPH Trials and What Has ReportedRetatrutide phase 3, trial by trial: the registered TRIUMPH and TRANSCEND studies, the results published so far, and what remains unknown.Read article
IllustrationGLP-1 and metabolic9 min readRetatrutide Side Effects: What the Clinical Trials RecordedRetatrutide side effects in phase 1 to 3 trials: gastrointestinal events, heart rate, hypotension, dysesthesia, discontinuations, and the…Read article
IllustrationGLP-1 and metabolic9 min readRetatrutide vs Semaglutide: What the Trials Can and Cannot CompareRetatrutide vs semaglutide: three receptors against one, the registered head-to-head trial that has not reported, and why cross-trial…Read article
IllustrationGLP-1 and metabolic10 min readSurvodutide: What the SYNCHRONIZE and MASH Trials FoundSurvodutide is an investigational GLP-1/glucagon dual agonist. Its phase 2 and phase 3 obesity and liver trials, results, side effects and…Read article
IllustrationGLP-1 and metabolic10 min readTirzepatide Cardiovascular Outcomes: What SURPASS-CVOT ShowedSURPASS-CVOT, SURPASS-4 and the SURPASS meta-analysis on tirzepatide and major cardiovascular events, with noninferiority and superiority…Read article
IllustrationGLP-1 and metabolic10 min readTirzepatide Side Effects: What SURPASS and SURMOUNT RecordedTirzepatide side effects from the SURPASS and SURMOUNT trials: gastrointestinal rates, discontinuations, gallbladder events and the…Read article
IllustrationGLP-1 and metabolic9 min readTirzepatide vs Semaglutide: What the Head-to-Head Trials ShowedTirzepatide vs semaglutide in the two head-to-head trials, SURPASS-2 and SURMOUNT-5: receptors, endpoints, results, tolerability and…Read article
IllustrationGLP-1 and metabolic9 min readWhat Is Tirzepatide? Structure, Mechanism, Trials and ApprovalsWhat tirzepatide is: a 39-residue GIP-based dual GIP/GLP-1 receptor agonist with a C20 fatty diacid, its trial programmes, and where it is…Read article
IllustrationGLP-1 and metabolic2 min readWhy Cagrilintide Solutions Turn Cloudy: Aggregation, Gelation and FibrilsCagrilintide aggregation explained: how cloudiness, gelation and fibrils differ, and why appearances cannot establish stability.Read article
IllustrationGLP-1 and metabolic2 min readGeneric Semaglutide in Canada: Patents, Equivalence and VerificationGeneric semaglutide in Canada explained: authorization, biosimilarity versus generic equivalence, product identity and verification.Read article
IllustrationGLP-1 and metabolic2 min readHow GLP-1, GIP and Glucagon Receptors Differ in Metabolic ResearchUnderstand GLP-1, GIP and glucagon receptors, the science behind semaglutide, tirzepatide and retatrutide.Read article
IllustrationGLP-1 and metabolic2 min readTirzepatide and Obstructive Sleep Apnea: Reading the Trial EvidenceExplore tirzepatide and obstructive sleep apnea research: trial endpoints, weight change, safety and Canadian regulatory distinctions.Read article
IllustrationGLP-1 and metabolic2 min readTirzepatide vs Eloralintide vs Mazdutide: What Makes Each Molecule Different?Compare tirzepatide, eloralintide and mazdutide by receptor targets, clinical research and evidence limits in our 2026 Canadian guide.Read article
IllustrationGLP-1 and metabolic7 min readCagrilintide and amylin: the fourth hormone in the incretin conversationCagrilintide is a long-acting amylin analogue, studied alone and with semaglutide as CagriSema. What amylin is, its receptors, and what the…Read article
Illustration5-Amino-1MQ7 min read5-Amino-1MQ and aged muscle stem cells: one paper, and what it reportedThe muscle thread for 5-Amino-1MQ rests on a single 2019 paper in aged mice. What it examined, the mechanism it proposed, and what is…Read article
IllustrationGLP-1 and metabolic8 min readRetatrutide and the triple agonist idea: what the trials examined and what is still unknownRetatrutide is investigational and approved by no regulator anywhere. Here is what its published trials examined and what they reported.Read article
IllustrationGLP-1 and metabolic8 min readTirzepatide and retatrutide: two receptor counts, two completely different regulatory positionsTirzepatide is an approved medicine; retatrutide is approved nowhere. What each trial programme examined, and why no head-to-head exists.Read article
Illustration5-Amino-1MQ6 min read5-Amino-1MQ is not a peptide: what NNMT inhibition is, and how far the work goes5-Amino-1MQ is a small molecule filed in peptide catalogues. What NNMT does, what three papers reported, and where the evidence stops.Read article
